IMARX THERAPEUTICS INC Form 10-Q/A December 30, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q/A Amendment No. 1

DescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescriptionDescription<l< th=""><th>5(d) of the Securities Exchange Act of 1934</th></l<>	5(d) of the Securities Exchange Act of 1934
o Transition report pursuant to Section 13 or 2 For the Transition Period from to Commission File Nu	
ImaRx Therap (Exact Name of Registrant as	· ·
Delaware (State or Other Jurisdiction of	86-0974730 (I.R.S. Employer
Incorporation or Organization) ImaRx Therapeutics, Inc. c/o Stoel Rives LLP	Identification No.)
201 S. Main Street, Suite 1100 Salt Lake City, Utah	84111
(Address of Principal Executive Offices) (801) 578	
(Registrant s Telephone Nun Indicate by check mark whether the registrant (1) has filed all	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. YES b NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES o NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated Filer o Accelerated Filer o Non-accelerated filer o Smaller reporting company b

Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO b

The number of shares outstanding of each of the issuer s classes of common stock, as of the latest practicable date is as follows:

Class
Common Stock \$0.0001 par value

Outstanding at December 29, 2009 11,665,733

EXPLANATORY NOTE

ImaRx Therapeutics, Inc. (the Company) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 (the Report) for the sole purpose of amending Exhibit Nos. 31.1 and 31.2 to include the introductory language of paragraph 4 and the language of paragraph 4(b) of Item 601(b)(31) Regulation S-K Except as described above, no other changes are made to Report, and this Form 10-Q/A does not amend, update or change any other Item or the disclosures in the Report in any way. This Form 10-Q/A does not reflect events occurring after the filing of the Report or modify or update those disclosures, including any exhibits to the Report, affected by subsequent events.

Item 6. Exhibits. Exhibits

Exhibit No.		7341 1	Incorporated by Reference			
	Exhibit Title	Filed Herewith	Form	Exhibit No.	File No.	Filing Date
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer	X				
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer	X				
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Office		10-Q	32	001-33043	November 16, 2009
		2				

Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10Q/A to be signed on its behalf by the undersigned, thereunto duly authorized.

IMARX THERAPEUTICS, INC.

Date: December 29, 2009 By: /s/ RICHARD LOVE

Richard Love,

Chairman of the Board

(Principal Executive Officer and Principal Financial

Officer)

Edgar Filing: IMARX THERAPEUTICS INC - Form 10-Q/A

EXHIBIT INDEX

Exhibit Index

			Incorporated by Reference			
Exhibit		Filed		Exhibit		
No.	Exhibit Title	Herewith	Form	No.	File No.	Filing Date
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer	X				
31.2	Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer	X				
32	Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Officer		10-Q	32	001-33043	November 16, 2009